导致无路易小体帕金森病的G2019S LRRK2突变。
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
作者信息
Gaig Carles, Martí María José, Ezquerra Mario, Rey Maria Jesús, Cardozo Adriana, Tolosa Eduardo
机构信息
Movement Disorders Unit, Department of Neurology, Institut Clínic de Neurociències, Hospital Clínic i Universitari de Barcelona, Barcelona, Spain.
出版信息
J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. doi: 10.1136/jnnp.2006.107904. Epub 2007 Jan 8.
Abstract
The G2019S leucine-rich repeat kinase 2 gene (LRRK2) mutation has been identified in a significant proportion of familial and sporadic cases of Parkinson's disease (PD). Until now, information on the neuropathological changes associated with the G2019S LRRK2 mutation has been sparse. We report a 77-year-old patient who presented with a 14 year history of PD but, unexpectedly, histopathological examination disclosed mild neuronal loss in the substantia nigra without alpha-synuclein, tau or ubiquitin cytoplasmic inclusions. A G2019S LRRK2 mutation was eventually detected. The present case confirms that clinical PD caused by G2019S mutations can be associated with non-specific nigral degeneration without Lewy bodies.
摘要
在相当一部分帕金森病（PD）的家族性和散发性病例中，已发现G2019S富亮氨酸重复激酶2基因（LRRK2）突变。到目前为止，与G2019S LRRK2突变相关的神经病理学变化的信息还很少。我们报告了一名77岁的患者，其有14年的帕金森病病史，但出乎意料的是，组织病理学检查显示黑质有轻度神经元丢失，无α-突触核蛋白、tau或泛素细胞质包涵体。最终检测到G2019S LRRK2突变。本病例证实，由G2019S突变引起的临床帕金森病可能与无路易小体的非特异性黑质变性有关。
相似文献
1
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.导致无路易小体帕金森病的G2019S LRRK2突变。
J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. doi: 10.1136/jnnp.2006.107904. Epub 2007 Jan 8.
2
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.导致无路易小体帕金森病的G2019S LRRK2突变。
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.08.2008.0632. Epub 2009 Jan 23.
3
Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.帕金森病伴 G2019S LRRK2 突变而无路易体病理。
Mov Disord Clin Pract. 2024 Jul;11(7):874-878. doi: 10.1002/mdc3.14068. Epub 2024 May 16.
4
Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.与LRRK2基因Ile1371Val突变相关的帕金森病神经病理学
Mov Disord. 2007 Jan 15;22(2):275-8. doi: 10.1002/mds.21281.
5
Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.LRRK2 基因突变致帕金森病的神经病理学研究
Mov Disord. 2009 Oct 15;24(13):1998-2001. doi: 10.1002/mds.22677.
6
TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.携带 G2019S LRRK2 突变和新的 p.Q124E MAPT 的患者的 TDP-43 病理学。
Neurobiol Aging. 2013 Dec;34(12):2889.e5-9. doi: 10.1016/j.neurobiolaging.2013.04.011. Epub 2013 May 9.
7
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.在帕金森综合征和额颞叶变性的病理系列中筛查LRRK2基因G2019S突变和1441密码子突变。
J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19.
8
Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.腺病毒介导的 G2019S LRRK2 的表达以激酶依赖的方式在帕金森病大鼠模型中诱导纹状体病理学。
Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.
9
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.与特发性病例相比，具有路易体病理的 G2019S LRRK2 帕金森病大脑中 α-突触核蛋白的可溶性和聚集特性存在差异。
Neurobiol Dis. 2013 Oct;58:183-90. doi: 10.1016/j.nbd.2013.05.017. Epub 2013 Jun 5.
10
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.LRRK2 基因突变相关帕金森病但无认知障碍患者的大脑皮层参与。
Acta Neuropathol. 2010 Aug;120(2):155-67. doi: 10.1007/s00401-010-0669-y. Epub 2010 Mar 16.
引用本文的文献
1
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases.路易体阴性的LRRK2突变病例中存在大量非包涵体型α-突触核蛋白病理改变。
Acta Neuropathol. 2025 May 2;149(1):41. doi: 10.1007/s00401-025-02871-w.
2
α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies.α-突触核蛋白与tau蛋白：相互作用、交叉播种以及将突触核蛋白病重新定义为复杂蛋白质病
Front Neurosci. 2025 Mar 27;19:1570553. doi: 10.3389/fnins.2025.1570553. eCollection 2025.
3
In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson's disease.深度质谱分析揭示磷酸化RAB12作为G2019S LRRK2驱动的帕金森病的血液生物标志物。
Brain. 2025 Jun 3;148(6):2075-2092. doi: 10.1093/brain/awae404.
4
Targets to Search for New Pharmacological Treatment in Idiopathic Parkinson's Disease According to the Single-Neuron Degeneration Model.根据单神经元退化模型寻找特发性帕金森病新的药物治疗靶点。
Biomolecules. 2024 Jun 8;14(6):673. doi: 10.3390/biom14060673.
5
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases.一种扩展抗体工具集的开发与验证，该工具集可捕捉路易体病中α-突触核蛋白的病理多样性。
NPJ Parkinsons Dis. 2023 Dec 7;9(1):161. doi: 10.1038/s41531-023-00604-y.
6
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.LRRK2 基因突变在帕金森病中的作用概述。
Biomolecules. 2023 May 16;13(5):845. doi: 10.3390/biom13050845.
7
AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer's and Parkinson's Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery.AmyP53，一种治疗阿尔茨海默病和帕金森病的治疗性肽候选药物：安全性、稳定性、药代动力学参数和鼻内递送至脑。
Int J Mol Sci. 2022 Nov 2;23(21):13383. doi: 10.3390/ijms232113383.
8
Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.LRRK2 ROC 结构域纯合突变：一种新型帕金森病遗传学模型。
J Biomed Sci. 2022 Aug 14;29(1):60. doi: 10.1186/s12929-022-00844-9.
9
Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers.血液细胞中 LRRK2 G2019S 突变携带者磷酸化 AKT 增加。
Ann Neurol. 2022 Nov;92(5):888-894. doi: 10.1002/ana.26469. Epub 2022 Sep 26.
10
Molecular mechanisms of amyloid formation in living systems.生物系统中淀粉样蛋白形成的分子机制。
Chem Sci. 2022 May 17;13(24):7080-7097. doi: 10.1039/d2sc01278b. eCollection 2022 Jun 22.
本文引用的文献
1
Parkinsonism, Lrrk2 G2019S, and tau neuropathology.帕金森综合征、亮氨酸重复激酶2基因G2019S突变与tau蛋白神经病理学
Neurology. 2006 Oct 24;67(8):1506-8. doi: 10.1212/01.wnl.0000240220.33950.0c.
2
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.西班牙帕金森病患者的LRRK2突变：频率、临床特征及不完全外显率
Arch Neurol. 2006 Mar;63(3):377-82. doi: 10.1001/archneur.63.3.377.
3
Biochemical and pathological characterization of Lrrk2.富含亮氨酸重复激酶2（Lrrk2）的生化与病理特征
Ann Neurol. 2006 Feb;59(2):315-22. doi: 10.1002/ana.20791.
4
Lrrk2 and Lewy body disease.富含亮氨酸重复激酶2与路易体病
Ann Neurol. 2006 Feb;59(2):388-93. doi: 10.1002/ana.20731.
5
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.对60个帕金森病家族的LRRK2基因进行综合分析。
Eur J Hum Genet. 2006 Mar;14(3):322-31. doi: 10.1038/sj.ejhg.5201539.
6
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.编码富含亮氨酸重复激酶2（dardarin，PARK8）的基因发生突变会导致家族性帕金森病：临床、病理、嗅觉及功能影像学和遗传学数据。
Brain. 2005 Dec;128(Pt 12):2786-96. doi: 10.1093/brain/awh667. Epub 2005 Nov 4.
7
An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.一种LRRK2突变作为原PARK8家族帕金森症的病因。
Ann Neurol. 2005 Jun;57(6):918-21. doi: 10.1002/ana.20484.
8
A common LRRK2 mutation in idiopathic Parkinson's disease.特发性帕金森病中一种常见的LRRK2突变。
Lancet. 2005;365(9457):415-6. doi: 10.1016/S0140-6736(05)17830-1.
9
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.对家族性帕金森病中单一常见的亮氨酸重复激酶2（LRRK2）突变进行基因筛查。
Lancet. 2005;365(9457):410-2. doi: 10.1016/S0140-6736(05)17828-3.
10
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.LRRK2基因的突变会导致具有多形性病理特征的常染色体显性帕金森病。
Neuron. 2004 Nov 18;44(4):601-7. doi: 10.1016/j.neuron.2004.11.005.
Zotero 插件